Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
$0.00
$0.00
$0.00
N/AN/A11,650 shsN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
$0.73
-0.6%
$1.06
$1.10
$13.78
$1.52M1.81236,278 shs27,836 shs
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
$62.98
$62.92
$36.47
$63.00
$4.73B1.541.97 million shsN/A
TRSBF
3SBio
$3.30
+1.5%
$2.18
$2.22
$3.35
N/AN/A902 shs3,044 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
0.00%0.00%0.00%0.00%+∞
Neuralstem, Inc. stock logo
CUR
Neuralstem
+2.01%+0.52%-4.01%+13.28%-83.93%
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
0.00%0.00%0.00%0.00%0.00%
TRSBF
3SBio
+1.54%+18.19%+26.92%+298.60%+330.14%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
N/AN/AN/AN/AN/AN/AN/AN/A
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
N/AN/AN/AN/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
0.00
N/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
0.00
N/AN/AN/A
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
0.00
N/AN/AN/A
TRSBF
3SBio
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/AN/AN/AN/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
$260K5.86N/AN/A$6.64 per share0.11
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
$4.64B1.02$5.31 per share11.85$45.24 per share1.39
TRSBF
3SBio
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/A-$0.16N/AN/AN/AN/AN/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
-$4.93MN/A0.00N/A-39,417.64%-170.51%-110.16%N/A
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
$401.01M$5.2811.93N/A8.64%12.32%7.34%N/A
TRSBF
3SBio
N/AN/A0.00N/AN/AN/AN/A8/20/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/AN/AN/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
N/AN/AN/AN/AN/A
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
$2.203.49%N/A41.67%1 Years
TRSBF
3SBio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
N/A
2.53
2.53
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
0.50
9.76
3.92
TRSBF
3SBio
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
32.45%
Neuralstem, Inc. stock logo
CUR
Neuralstem
38.30%
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
88.08%
TRSBF
3SBio
N/A

Insider Ownership

CompanyInsider Ownership
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
5.38%
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
23.30%
TRSBF
3SBio
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/AN/AN/ANot Optionable
Neuralstem, Inc. stock logo
CUR
Neuralstem
62.10 millionN/ANot Optionable
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
1,76075.05 million57.56 millionOptionable
TRSBF
3SBio
5,411N/AN/ANot Optionable

Top Headlines

View All Headlines
Abattis Bioceuticals stock logo

Abattis Bioceuticals OTCMKTS:ATTBF

Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.

Neuralstem stock logo

Neuralstem NASDAQ:CUR

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

M.D.C. stock logo

M.D.C. NYSE:MDC

M.D.C. Holdings, Inc., through its subsidiaries, engages in the homebuilding and financial service businesses. Its homebuilding operations include purchasing finished lots or developing lots for the construction and sale primarily of single-family detached homes to first-time and first-time move-up homebuyers under the Richmond American Homes name. The company conducts its homebuilding operations in Arizona, California, Nevada, New Mexico, Oregon, Texas, Washington, Colorado, Idaho, Utah, Alabama, Florida, Maryland, Pennsylvania, Tennessee, and Virginia. Its financial services operations comprise originating mortgage loans primarily for homebuyers; providing insurance coverage primarily to its homebuilding subsidiaries and subcontractors for homes sold by its homebuilding subsidiaries, and for work performed in completed subdivisions; acting as a re-insurer on the claims; selling third-party personal property and casualty insurance products to homebuyers; and offering title agency services to homebuilding subsidiaries and customers in Colorado, Florida, Maryland, Nevada, Pennsylvania, and Virginia. The company was founded in 1972 and is headquartered in Denver, Colorado. As of April 19, 2024, M.D.C. Holdings, Inc. operates as a subsidiary of SH Residential Holdings, LLC.

3SBio OTCMKTS:TRSBF

$3.30 +0.05 (+1.54%)
As of 07/3/2025 12:54 PM Eastern

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium. In addition, the company provides MN709 Minoxidil Foam and Nalfuraphine hydrochloride tablets. Further, it provides trading, project management and consultation, technology, sports, financial, investment advisory, as well as manufactures medical devices; and offers agricultural services. The company has collaboration agreements with companies, such as Toray. 3SBio Inc. was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.